Kiran Godse. (2017). Secukinumab - first in class interleukin-17A inhibitor for the treatment of psoriasis. Wolters Kluwer Medknow Publications.
Chicago Style (17th ed.) CitationKiran Godse. Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis. Wolters Kluwer Medknow Publications, 2017.
MLA (9th ed.) CitationKiran Godse. Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis. Wolters Kluwer Medknow Publications, 2017.
Warning: These citations may not always be 100% accurate.